文献速递肾移植肾小球疾病

mTOR抑制剂与CNI方案对肾移植受者CMV及BKPyV感染影响的系统评价与荟萃分析

CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.
PubMed 文献 · Clin J Am Soc Nephrol · 2017-06-02

该系统评价与荟萃分析纳入28项随机对照试验共6211例肾移植受者,比较mTOR抑制剂方案与钙调神经磷酸酶抑制剂(CNI)方案。结果显示mTOR抑制剂组巨细胞病毒(CMV)感染发生率显著降低(比较1 RR 0.54,95%CI 0.41-0.72;比较2 RR 0.43,95%CI 0.24-0.80),但BK多瘤病毒(BKPyV)感染证据不确定。mTOR抑制剂组严重不良事件、急性排斥、蛋白尿和伤口愈合并发症更多。

要点

  • mTOR抑制剂方案较CNI方案显著降低肾移植受者CMV感染风险。
  • mTOR抑制剂方案对BKPyV感染的影响证据不确定,未能证实或排除。
  • mTOR抑制剂联合减量CNI方案eGFR和急性排斥率与标准CNI方案相似,但蛋白尿和伤口并发症更多。

核心结论

  • 中至高质量证据表明,肾移植受者使用mTOR抑制剂方案较CNI方案可降低CMV感染风险。
  • mTOR抑制剂联合减量CNI方案在eGFR、急性排斥和严重不良事件方面与标准CNI方案相似,但蛋白尿和伤口愈合并发症发生率更高。

研究设计与样本

  • 系统评价与荟萃分析,检索截至2016年1月的随机对照试验。
  • 共纳入28项随机对照试验,6211例肾移植受者。
  • 分为比较1(mTOR抑制剂 vs CNI)和比较2(mTOR抑制剂+减量CNI vs 常规剂量CNI)。
  • 采用GRADE方法评估证据质量。

主要发现

  • 比较1中mTOR抑制剂组CMV感染发生率降低(RR 0.54,95%CI 0.41-0.72),证据质量高。
  • 比较2中mTOR抑制剂+减量CNI组CMV感染发生率降低(RR 0.43,95%CI 0.24-0.80),证据质量中等。
  • 两个比较中mTOR抑制剂组对BKPyV感染的影响证据均不确定。
  • 比较1中mTOR抑制剂组严重不良事件和急性排斥更多,eGFR更高(平均差4.07 ml/min per 1.73 m2,95%CI 1.34-6.80)。
  • 两个比较中mTOR抑制剂组蛋白尿和伤口愈合并发症更多,移植肾丢失无差异。

关键数值与推荐

  • CMV感染风险比:比较1 RR 0.54(95%CI 0.41-0.72),比较2 RR 0.43(95%CI 0.24-0.80)。
  • eGFR平均差:比较1为4.07 ml/min per 1.73 m2(95%CI 1.34-6.80)。
  • BKPyV感染证据不确定,未能证实或排除风险降低。

临床怎么用

  • 对于CMV感染高风险肾移植受者,可考虑mTOR抑制剂方案以降低CMV感染风险。
  • 选择mTOR抑制剂联合减量CNI方案时需权衡蛋白尿和伤口愈合并发症风险。
  • BKPyV感染预防决策不能仅依据mTOR抑制剂方案,需结合其他监测措施。

局限性

  • 检索截止至2016年1月,可能未纳入后续研究。
  • BKPyV感染相关证据不足,无法得出明确结论。
  • 部分比较的证据质量仅为中等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The objective of this meta-analysis is to compare the incidences of cytomegalovirus and BK polyoma virus infections in renal transplant recipients receiving a mammalian target of rapamycin inhibitor (mTOR)-based regimen compared with a calcineurin inhibitor-based regimen. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a comprehensive search for randomized, controlled trials up to January of 2016 addressing our objective. Other outcomes included acute rejection, graft loss, serious adverse events, proteinuria, wound-healing complications, and eGFR. Two review authors selected eligible studies, abstracted data, and assessed risk of bias. We assessed quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation methodology. RESULTS: We included 28 randomized, controlled trials with 6211 participants classified into comparison 1: mTOR inhibitor versus calcineurin inhibitor and comparison 2: mTOR inhibitor plus reduced dose of calcineurin inhibitor versus regular dose of calcineurin inhibitor. Results showed decreased incidence of cytomegalovirus infection in mTOR inhibitor-based group in both comparison 1 (risk ratio, 0.54; 95% confidence interval, 0.41 to 0.72), with high quality of evidence, and comparison 2 (risk ratio, 0.43; 95% confidence interval, 0.24 to 0.80), with moderate quality of evidence. The available evidence neither confirmed nor ruled out a reduction of BK polyoma virus infection in mTOR inhibitor-based group in both comparisons. Secondary outcomes revealed more serious adverse events and acute rejections in mTOR inhibitor-based group in comparison 1 and no difference in comparison 2. There was no difference in graft loss in both comparisons. eGFR was higher in the mTOR inhibitor-based group in comparison 1 (mean difference =4.07 ml/min per 1.73 m2; 95% confidence interval, 1.34 to 6.80) and similar to the calcineurin inhibitor-based group in comparison 2. More proteinuria and wound-healing complications occurred in the mTOR inhibitor-based groups. CONCLUSIONS: We found moderate- to high-quality evidence of reduced risk of cytomegalovirus infection in renal transplant recipients in the mTOR inhibitor-based compared with the calcineurin inhibitor-based regimen. Our review also suggested that a combination of a mTOR inhibitor and a reduced dose of calcineurin inhibitor may be associated with similar eGFR and rates of acute rejections and serious adverse events compared with a standard calcineurin inhibitor-based regimen at the expense of higher incidence of proteinuria and wound-healing complications.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Mallat SG, Tanios BY, Itani HS, et al. CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials. Clin J Am Soc Nephrol. 2017. PMID: 28576905. doi:10.2215/CJN.13221216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。